ANZCTR - Registration

The ANZCTR website is back online for trial registration and updates. We apologise for any inconvenience caused while the site was inactive.

With activity expected to increase on the ANZCTR again, there may be extended wait times while we process pending studies, with priority being given to those trials submitted in February. Thank you for your patience.

Reset your password and enable multi-factor authentication (MFA)

For ANZCTR account holders: to help ensure the cyber safety of your account, you’ll need to reset your password and set-up multi-factor authentication (MFA) as per the instructions below.

Go to the Login page, click ‘reset password’ and follow the instructions.
Check your email for the link to set a new password.
Create a new password that meets requirements.
Return to the Login page and enter your new password. A verification code will be sent to your email.
Check your email for the code and enter it on the Login page. If the code is entered incorrectly, you can re-enter the correct one or request a new one.

Learn more about MFA and its importance on the Australian Signals Directorate website.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers

Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01029652

Registration number

NCT01029652

Ethics application status

Date submitted

9/12/2009

Date registered

10/12/2009

Date last updated

30/01/2014

Titles & IDs

Public title

Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicine Including a 12 Weeks Extension and an Open-label 48 Weeks Extension Study

Scientific title

A 12 Weeks Randomized, Controlled Core Study of ACZ885 (Canakinumab) on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective, Including a 12-week Double-blind Extension Study and an Open-label 48 Week Extension Study

Secondary ID [1]

2009-015018-23

Secondary ID [2]

CACZ885H2356

Universal Trial Number (UTN)

Trial acronym

ß-RELIEVED

Linked study record

Health condition

Health condition(s) or problem(s) studied:

Acute Gout

Condition category

Condition code

Musculoskeletal

Other muscular and skeletal disorders

Inflammatory and Immune System

Other inflammatory or immune system disorders

Intervention/exposure

Study type

Interventional

Description of intervention(s) / exposure

Treatment: Drugs - Canakinumab 150 mg
Treatment: Drugs - Triamcinolone acetonide 40 mg
Treatment: Drugs - Placebo to canakinumab
Treatment: Drugs - Placebo to triamcinolone acetonide

Experimental: Canakinumab 150 mg - Patients received 1 subcutaneous (sc) injection of canakinumab 150 mg and 1 intramuscular (im) injection of placebo to triamcinolone acetonide on Day 1. Patients could receive re-dose of study drug on demand upon occurrence of new flares, but re-dosing could not occur until 14 days had elapsed after previous dose. Patients completing 12 weeks core study were allowed to continue treatment in another 12-week extension for any new gout flare on demand with same treatment as assigned in core study.

After completing the first extension, patients were offered to enter second extension study, whereby all patients were treated open-label "on demand" with canakinumab 150 mg sc upon new flare for 1 year for a total duration of 18 months following randomization in core study. Patients completing first 12 weeks extension study were allowed to continue to be treated in another single-arm, open-label 48 weeks extension when all patients from both treatment arms received canakinumab on demand

Active comparator: Triamcinolone acetonide 40 mg - Patients received 1 intramuscular (im) injection of triamcinolone acetonide 40 mg and 1 subcutaneous (sc) injection of placebo to canakinumab on Day 1. Patients could receive a re-dose of study drug on demand upon the occurrence of new flares, but re-dosing could not occur until 14 days had elapsed after the previous dose. Patients completing the 12 weeks core study were allowed to continue to be treated in another 12 weeks extension study for any new gout flare on demand with the same treatment as assigned in the core study.

Patients under this arm who agreed to continue to 2nd extension period of 12 months, were switched to canakinumab 150 mg sc for any new gout flare during this period Triamcinolone acetonide was not to be administered in the 48-week session.

Treatment: Drugs: Canakinumab 150 mg
Canakinumab 150 mg was supplied in 6 mL glass vials each containing nominally 150 mg canakinumab (plus 20% overfill).

Treatment: Drugs: Triamcinolone acetonide 40 mg
Triamcinolone acetonide 40 mg was supplied as a suspension.

Treatment: Drugs: Placebo to canakinumab
Placebo to canakinumab was supplied in 6 mL glass vials containing placebo powder as a lyophilized cake.

Treatment: Drugs: Placebo to triamcinolone acetonide
Placebo triamcinolone acetonide was supplied as a lipid emulsion similar in appearance to triamcinolone acetonide.

Intervention code [1]

Treatment: Drugs

Comparator / control treatment

Control group

Outcomes

Primary outcome [1]

Time to First New Flare

Assessment method [1]

Kaplan-Meier estimates of time to first new flare and confidence intervals were determined. For patients with event, time to event = (date of event - date of first dose of study drug + 1). Patients met definition of new flare if they had: * Flare in joint, not a previously affected joint (at baseline or during study) * Flare in joint previously affected (at baseline or during study) after previous flare in joint has resolved completely. Patients did not meet criterion of having new gout flare if: · Increasing/renewed gout pain in an affected joint before flare has resolved completely.

Timepoint [1]

12 weeks

Primary outcome [2]

Self-assessed Pain Intensity in the Joint Most Affected at Baseline Measured on a Visual Analog Scale (0-100mm VAS)

Assessment method [2]

Patients scored their pain intensity in the joint most affected at baseline on a 0-100 mm VAS, ranging from no pain (0) to unbearable pain (100), at 72 hours post-dose. Scores on the 100 mm linear scale were measured to the nearest millimeter from the left. The ANCOVA analysis included treatment group, Baseline VAS score, and body mass index (BMI) at Baseline as covariates.

Timepoint [2]

72 hours post-dose (randomization)

Primary outcome [3]

Number of Participants With Adverse Events (AE), Death and Serious Adverse Events (24 Weeks Overall)

Assessment method [3]

This was the primary endpoint of both extension studies. Adverse event is defined as any unfavorable and unintended diagnosis, symptom, sign(including an abnormal laboratory finding),syndrome or disease which either occurs during the study, having been absent at baseline, or,if present at baseline, appears to worsen. Serious adverse event is defined as any untoward medical occurrence that results in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, or is a congenital anomaly/birth defect.

Timepoint [3]

24 weeks overall

Primary outcome [4]

Number of Participants With Adverse Events (AE), Death and Serious Adverse Events (72 Weeks Overall)

Assessment method [4]

Timepoint [4]

72 weeks overall

Secondary outcome [1]

Time to at Least a 50% Reduction in Self-assessed Pain Intensity in the Joint Most Affected at Baseline Measured on a Visual Analog Scale (0-100mm VAS)

Assessment method [1]

The Kaplan-Meier estimates of the time to at least a 50% reduction in self-assessed pain intensity in the joint most affected at baseline was determined along with the 95% confidence interval. Patients scored their pain intensity on a 0-100 mm VAS, ranging from no pain (0) to unbearable pain (100). Scores on the 100 mm linear scale were measured to the nearest millimeter from the left. Pain was scored at Baseline; at 6 and 12 hours post-dose; and at 1, 2, 3, 4, 5, 6, and 7 days post-dose.

Timepoint [1]

From baseline to 7 days post dose (randomization)

Secondary outcome [2]

Time to Complete Resolution of Pain

Assessment method [2]

Patients scored their pain intensity on a 5-point Likert scale (none, mild, moderate, severe, extreme). Complete Resolution of Pain is defined as no pain (None) on the Likert Scale. Pain was scored at Baseline; at 6 and 12 hours post-dose; and at 1, 2, 3, 4, 5, 6, and 7 days post-dose. The Kaplan-Meier estimates of time to complete resolution of self-assessed pain intensity in the joint most affected and their confidence intervals were determined.

Timepoint [2]

7 days post-dose (randomization)

Secondary outcome [3]

Percentage of Participants With Complete Resolution of Pain

Assessment method [3]

Patients scored their pain intensity on a 5-point Likert scale (none, mild, moderate, severe, extreme). Pain was scored at Baseline; at 6 and 12 hours post-dose; and at 1, 2, 3, 4, 5, 6, and 7 days post-dose. Complete Resolution of Pain is defined as no pain (None) on the Likert Scale. The Kaplan-Meier estimates of cumulative event rate = percentage of participants with event up to the end of the time interval.

Timepoint [3]

7 days post-dose (randomization)

Secondary outcome [4]

Percentage of Participants With at Least 1 New Gout Flare During the 12 Weeks

Assessment method [4]

Patients met definition of new flare if they had: * Flare in joint, not a previously affected joint (at baseline or during study) * Flare in joint previously affected (at baseline or during study) after previous flare in joint has resolved completely. Patients did not meet criterion of having new gout flare if: · Increasing/renewed gout pain in an affected joint before the flare has resolved completely.

Timepoint [4]

12 weeks

Secondary outcome [5]

Mean Number of New Gout Flares Per Patient

Assessment method [5]

Timepoint [5]

12 weeks

Secondary outcome [6]

SF36 Physical Function Score at Week 12

Assessment method [6]

The SF-36 measures the impact of disease on overall quality of life (QoL). This 36-item survey has 8 subscales that can be aggregated into physical- and mental-component summary scores. Scores are standardized with the use of norm-based methods based on an assessment of the general U.S. population free of chronic conditions. Scores range from 1-100 with a mean=50 and a standard deviation=10. A higher score indicates less impact on QoL. A negative change score indicates improvement. An ANCOVA model was used with treatment group and baseline SF-36 physical function subscore as covariates.

Timepoint [6]

Week 12

Secondary outcome [7]

Time to First New Flare

Assessment method [7]

Kaplan-Meier (KM) estimates of time to first new flare and confidence intervals were determined. Patients met definition of new flare if they had: * Flare in joint, not a previously affected joint (at baseline or during study) * Flare in joint previously affected (at baseline or during study) after previous flare in joint has resolved completely. Patients did not meet criterion of having new gout flare if: · Increasing/renewed gout pain in an affected joint before the flare has resolved completely.

Timepoint [7]

24 weeks

Secondary outcome [8]

Mean Number of New Gout Flares Per Patient During the 24 Weeks of the Study

Assessment method [8]

Timepoint [8]

24 weeks

Secondary outcome [9]

Time to First Intake of Rescue Medication After the Last Post Baseline Flare.

Assessment method [9]

The Kaplan-Meier estimates of medians and 95% confidence intervals were used to calculate the endpoint.

Timepoint [9]

72 hours post-dose for the last post-baseline flare (during 24 weeks overall)

Secondary outcome [10]

Patient's Assessment of Gout Pain Intensity in the Most Affected Joint on a Visual Analog Scale (VAS) in Extension

Assessment method [10]

Patients scored their pain intensity in the joint most affected at baseline on a 0-100 mm VAS, ranging from no pain (0) to unbearable pain (100). Scores on the 100 mm linear scale were measured to the nearest millimeter from the left. The ANCOVA analysis included treatment group, Baseline VAS score, and body mass index (BMI) at Baseline as covariates.

Timepoint [10]

72 hours post-dose for the last post-baseline flare (during 24 weeks overall)

Secondary outcome [11]

Percentage of Participants With Maximum Severity of Last Post-baseline Flare (5-point Likert Scale)

Assessment method [11]

Maximum severity is the maximum Likert score recorded after the start of the flare. Participant scored their current pain intensity in the most affected joint of the gout flare on a 5-point Likert Scale (none, mild, moderate, severe, extreme). It participant had a new flare, they also scored the maximum amount of acute gout pain in the most affected joint since the onset of a new flare on 5 point Likert scale (none, mild, moderate, severe, extreme).

Timepoint [11]

Last post-baseline flare (during 24 weeks overall)

Secondary outcome [12]

Amount of Rescue Medication Taken

Assessment method [12]

Patients who had difficulty in tolerating their pain were allowed to take rescue medication after the 6-hour post-dose pain assessments as follows: * Acetaminophen (paracetamol) 500 mg and/ or codeine 30 mg as required. A maximum of 1 g/dose or 3 g/day of acetaminophen and 30 mg/ dose or 180 mg/day of codeine was allowed. * If they had insufficient pain relief, patients were allowed to take a maximum of 30 mg of oral prednisolon as required per day for 2 days followed by up to 20 mg of prednisolone as required subsequent days within 7 days of a gout flare.

Timepoint [12]

7 days last post-baseline flare (during 24 weeks)

Secondary outcome [13]

Percentage of Participants Who Took Rescue Medication

Assessment method [13]

Patients who had difficulty in tolerating their pain were allowed to take rescue medication after the 6-hour post-dose pain assessments. Permitted rescue medications included acetaminophen 500 mg and/ or codeine 30 mg as needed. If they had insufficient pain relief, patients were allowed to take a maximum of 30 mg of oral prednisolone as needed per day for 2 days followed by up to 20 mg of prednisolone as needed per day for 3 subsequent days within 7 days after randomization or after re-dose/injection administration.

Timepoint [13]

during 12 weeks core, 24 weeks overall

Secondary outcome [14]

High-sensitivity C-reactive Protein (hsCRP) and Serum Amyloid A Protein (SAA) Levels for Core and 24 Weeks Overall

Assessment method [14]

High sensitivity C-reactive protein (hsCRP) and serum amyloid A (SAA) were determined in blood serum in order to identify the presence of inflammation, to determine its severity, and to monitor the response to treatment. Analytes were measured by a central laboratory. The analysis included treatment group, log-transformed protein level at baseline, and body mass index (BMI) at baseline as covariates.

Timepoint [14]

72 hours post-dose (randomization), 72 hours post-dose for the last post-baseline flare (during 24 weeks overall)

Secondary outcome [15]

Physician's Global Assessment of Response to Treatment

Assessment method [15]

Timepoint [15]

72 hours post-dose (randomization), 72 hours post-dose for the last post-baseline flare (during 24 weeks overall)

Secondary outcome [16]

Patient's Global Assessment of Response to Treatment

Assessment method [16]

Timepoint [16]

72 hours post-dose (randomization), 72 hours post-dose for the last post-baseline flare (during 24 weeks overall)

Secondary outcome [17]

Physician's Assessment of Tenderness, Swelling, and Erythema of the Most Affected Joint

Assessment method [17]

The study physician assessed the most affected joint for: Tenderness on a 0-3 point scale: No pain, patient states that "there is pain", patient states "there is pain and winces", and patient states "there is pain, winces, and withdraws" on palpation or passive movement of the affected study joint; Swelling on a 0-3 point scale: No swelling, palpable, visible, and bulging beyond the joint margins; and Erythema: Present or absent. The percentage of patients in each category is reported.

Timepoint [17]

72 hours post-dose (randomization), 72 hours post-dose for the last post-baseline flare (during 24 weeks overall)

Secondary outcome [18]

Physician's Assessment of Range of Motion of the Most Affected Joint

Assessment method [18]

The study physician assessed the range of motion of the most affected joint for range of motion on a 5-point Likert scale: Normal, mildly restricted, moderately restricted, severely restricted, immobilized. The percentage of patients in each category is reported.

Timepoint [18]

72 hours post-dose (randomization), 72 hours post-dose for the last post-baseline flare (24 weeks overall)

Secondary outcome [19]

Patient's Assessment of Gout Pain Intensity in the Most Affected Joint (Likert Scale)

Assessment method [19]

Timepoint [19]

7 days post dose (randomization), 24 weeks post-dose

Secondary outcome [20]

Time to First New Flare: Survival Analysis by Treatment (72 Weeks Overall)

Assessment method [20]

Timepoint [20]

72 weeks overall

Secondary outcome [21]

Flare Rate Per Year

Assessment method [21]

Flare rate was calculated as the number of new flares over the period of observation in years. Flare rate was calculated using only those new flares before switching to canakinumab. Patients met definition of new flare if they had: * Flare in joint, not a previously affected joint (at baseline or during study) * Flare in joint previously affected (at baseline or during study) after previous flare in joint has resolved completely. Patients did not meet criterion of having new gout flare if: · Increasing/renewed gout pain in an affected joint before the flare has resolved completely.

Timepoint [21]

72 weeks overall

Secondary outcome [22]

High-sensitivity C-reactive Protein (hsCRP) Levels for Patients Re-treated With or Switched to Canakinumab

Assessment method [22]

High sensitivity C-reactive protein (hsCRP) levels were determined in blood serum in order to identify the presence of inflammation, to determine its severity, and to monitor the response to treatment. Analytes were measured by a central laboratory. The treatment effect reported for canakinumab arm was for last post-baseline flare after re-treated with canakinumab and for patient which switched to Canakinumab arm was for first post-baseline flare after receiving the first dose of canakinumab.

Timepoint [22]

24 hours, 72 hours, 7 days, 4 weeks, 8 weeks and 12 weeks post-dose for the last post-baseline flare for patients re-treated with canakinumab or first post-baseline flare treated with canakinumab for patients switched treatment (during 72 weeks overall)

Secondary outcome [23]

Serum Amyloid A Protein (SAA) Levels for Patients Re-treated With or Switched to Canakinumab

Assessment method [23]

Serum Amyloid A Protein (SAA) levels were determined in blood serum in order to identify the presence of inflammation, to determine its severity, and to monitor the response to treatment. Analytes were measured by a central laboratory. The treatment effect reported for canakinumab arm was for last post-baseline flare after re-treated with canakinumab and for patient which switched to Canakinumab arm was for first post-baseline flare after receiving the first dose of canakinumab.

Timepoint [23]

Secondary outcome [24]

Physician's Global Assessment of Response to Treatment for Patients Re-treated or Switched to Canakinumab

Assessment method [24]

The study physician made a global assessment of the patient's response to treatment using a 5-point Likert scale: Very good, good, fair, poor, very poor. The percentage of patients in each category is reported. The physician completed the assessment without viewing any of the patient's assessments (pain intensity \[Visual Analog Scale and Likert scale\] and patient's global assessment of response to treatment). The treatment effect reported for canakinumab arm was for last post-baseline flare after re-treated with canakinumab and for patient which switched to Canakinumab arm was for first post-baseline flare after receiving the first dose of canakinumab.

Timepoint [24]

72 hours post-dose , 7 days post-dose for the last post-baseline flare for patients re-treated with canakinumab or first post-baseline flare treated with canakinumab for patients switched treatment (during 72 weeks overall)

Secondary outcome [25]

Patient's Assessment of Gout Pain Intensity in the Currently Most-affected Joint (Likert Scale)

Assessment method [25]

Participant scored their current pain intensity in the most affected joint of the gout flare on a 5-point Likert Scale (none, mild, moderate, severe, extreme). It participant had a new flare, they also scored the maximum amount of acute gout pain in the most affected joint since the onset of a new flare on 5 point Likert scale (none, mild, moderate, severe, extreme). The treatment effect reported for canakinumab arm was for last post-baseline flare after re-treated with canakinumab and for patient which switched to Canakinumab arm was for first post-baseline flare after receiving the first dose of canakinumab.

Timepoint [25]

72 hours post-dose , 7 days post dose for the last post-baseline flare for patients re-treated with canakinumab or the first post-baseline flare treated with canakinumab for patients who switched treatment (during 72 weeks overall)

Secondary outcome [26]

Patient's Global Assessment of Response to Treatment for Patients Re-treated or Switched to Canakinumab

Assessment method [26]

Patients made a global assessment of response to treatment using a 5-point Likert scale: Excellent, good, acceptable, slight, poor. Percentage of participants in each category for both core and extension periods were measured. The treatment effect reported for canakinumab arm was for last post-baseline flare after re-treated with canakinumab and for patient which switched to Canakinumab arm was for first post-baseline flare after receiving the first dose of canakinumab.

Timepoint [26]

Secondary outcome [27]

Physician's Assessment of Joint Tenderness for Patients Re-treated or Switched to Canakinumab

Assessment method [27]

The study physician assessed the most affected joint for: Tenderness on a 0-3 point scale: No pain, patient states that "there is pain", patient states "there is pain and winces", and patient states "there is pain, winces, and withdraws" on palpation or passive movement of the affected study joint; The percentage of patients in each category is reported. The treatment effect reported for canakinumab arm was for last post-baseline flare after re-treated with canakinumab and for patient which switched to Canakinumab arm was for first post-baseline flare after receiving the first dose of canakinumab.

Timepoint [27]

72 hours post-dose , 7 days post dose last post-baseline flare for patients re-treated with canakinumab or the first post-baseline flare treated with canakinumab for patients who switched treatment (during 72 weeks overall)

Secondary outcome [28]

Physician's Assessment of Joint Swelling for Patients Re-treated or Switched to Canakinumab

Assessment method [28]

The study physician assessed the most affected joint for: Swelling on a 0-3 point scale: No swelling, palpable, visible, and bulging beyond the joint margins; The percentage of patients in each category is reported. The treatment effect reported for canakinumab arm was for last post-baseline flare after re-treated with canakinumab and for patient which switched to Canakinumab arm was for first post-baseline flare after receiving the first dose of canakinumab.

Timepoint [28]

Secondary outcome [29]

Physician's Assessment of Erythema for Patients Re-treated or Switched to Canakinumab

Assessment method [29]

The study physician assessed the most affected joint for Erythema: Present or absent. The percentage of patients in each category is reported. The treatment effect reported for canakinumab arm was for last post-baseline flare after re-treated with canakinumab and for patient which switched to Canakinumab arm was for first post-baseline flare after receiving the first dose of canakinumab.

Timepoint [29]

Eligibility

Key inclusion criteria

Core Study:

Inclusion criteria:

* Meeting the American College of Rheumatology (ACR) 1977 preliminary criteria for the classification of acute arthritis of primary gout
* Onset of current acute gout flare within 5 days prior to study entry
* Baseline pain intensity = 50 mm on the 0-100 mm visual analog scale (VAS)
* History of = 3 gout flares within the 12 months prior to study entry
* Contraindication, intolerance, or lack of efficacy for non-steroidal anti-inflammatory drugs (NSAIDs) and/or colchicine

Minimum age

18 Years

Maximum age

85 Years

Sex

Both males and females

Can healthy volunteers participate?

Key exclusion criteria

Exclusion criteria:

* Rheumatoid arthritis, evidence/suspicion of infectious/septic arthritis, or other acute inflammatory arthritis
* Presence of severe renal function impairment
* Use of specified pain relief medications or biologics ( corticosteroids, narcotics, paracetamol/acetominophen, ibuprofen, colchicine, IL-blocker, and tumor necrosis factor inhibitor) within specified periods prior to study entry
* Live vaccinations within 3 months prior to randomization
* Requirement for administration of antibiotics against latent tuberculosis (TB)
* Refractory heart failure (Stage D)
* Unstable cardiac arrhythmias or unstable symptomatic coronary ischemia
* Any active or recurrent bacterial, fungal, or viral infection

Extension Study 1:

Inclusion Completion of the Core study. A patient was defined as completing the core study if they completed the study up to and including visit 7.

Exclusion

- Continuation in this extension study was considered inappropriate by the treating physician.

Extension Study 2:

Inclusion Completed of the first extension study CACZ885H2356E1. A patient was defined as completing the first extension study if they completed the study up to and including Visit 10).

Exclusion

-Continuation in this extension study was considered inappropriate by the treating physician

Other protocol-defined inclusion-exclusion criteria applied to the core and extension studies.

Study design

Purpose of the study

Treatment

Allocation to intervention

Randomised controlled trial

Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)

Methods used to generate the sequence in which subjects will be randomised (sequence generation)

Masking / blinding

Blinded (masking used)

Who is / are masked / blinded?

The people receiving the treatment/s

The people analysing the results/data

Intervention assignment

Parallel

Other design features

Phase

Phase 3

Type of endpoint/s

Statistical methods / analysis

Recruitment

Recruitment status

Completed

Data analysis

Reason for early stopping/withdrawal

Other reasons

Date of first participant enrolment

Anticipated

Actual

1/12/2009

Date of last participant enrolment

Anticipated

Actual

Date of last data collection

Anticipated

Actual

1/10/2010

Sample size

Target

Accrual to date

Final

230

Recruitment in Australia

Recruitment state(s)

NSW,VIC

Recruitment hospital [1]

Novartis Investigative Site - Darlinghurst

Recruitment hospital [2]

Novartis Investigative Site - Fitzroy

Recruitment hospital [3]

Novartis Investigative Site - Heidelberg

Recruitment hospital [4]

Novartis Investigative Site - Daw Park SA

Recruitment postcode(s) [1]

- Darlinghurst

Recruitment postcode(s) [2]

- Fitzroy

Recruitment postcode(s) [3]

- Heidelberg

Recruitment postcode(s) [4]

- Daw Park SA

Recruitment outside Australia

Country [1]

Belgium

State/province [1]

Gozee

Country [2]

Canada

State/province [2]

Newfoundland and Labrador

Country [3]

Canada

State/province [3]

Ontario

Country [4]

Colombia

State/province [4]

Barranquilla

Country [5]

Colombia

State/province [5]

Bogota

Country [6]

Colombia

State/province [6]

Bucaramanga

Country [7]

Estonia

State/province [7]

Parnu

Country [8]

Estonia

State/province [8]

Tallinn

Country [9]

Estonia

State/province [9]

Tartu

Country [10]

Germany

State/province [10]

Bayreuth

Country [11]

Germany

State/province [11]

Berlin

Country [12]

Germany

State/province [12]

Leipzig

Country [13]

Germany

State/province [13]

Loehne

Country [14]

Germany

State/province [14]

Magdeburg

Country [15]

Germany

State/province [15]

Munich

Country [16]

Guatemala

State/province [16]

Guatemala City

Country [17]

Latvia

State/province [17]

Riga

Country [18]

Latvia

State/province [18]

Valmiera

Country [19]

Lithuania

State/province [19]

Kaunas

Country [20]

Lithuania

State/province [20]

Kedainiai

Country [21]

Lithuania

State/province [21]

Klaipeda

Country [22]

Lithuania

State/province [22]

Siauliai

Country [23]

Lithuania

State/province [23]

Vilnius

Country [24]

Mexico

State/province [24]

Culiacan

Country [25]

Mexico

State/province [25]

Guadalajara

Country [26]

Mexico

State/province [26]

Mexicali

Country [27]

Norway

State/province [27]

Oslo

Country [28]

Poland

State/province [28]

Katowice

Country [29]

Poland

State/province [29]

Kutno

Country [30]

Poland

State/province [30]

Lublin

Country [31]

Poland

State/province [31]

Wroclaw

Country [32]

Russian Federation

State/province [32]

Moscow

Country [33]

Russian Federation

State/province [33]

Yaroslavl

Country [34]

Russian Federation

State/province [34]

Yekaterinburg

Country [35]

Singapore

State/province [35]

Singapore

Country [36]

Sweden

State/province [36]

Goeteborg

Country [37]

Sweden

State/province [37]

Stockholm

Country [38]

Switzerland

State/province [38]

Lausanne

Country [39]

Ukraine

State/province [39]

Donetsk

Country [40]

Ukraine

State/province [40]

Kyiv

Country [41]

Ukraine

State/province [41]

Lviv

Country [42]

Ukraine

State/province [42]

Zaporizhzhya

Funding & Sponsors

Primary sponsor type

Commercial sector/industry

Name

Novartis Pharmaceuticals

Country

Ethics approval

Ethics application status

Summary

Brief summary

The purpose of the 12-week core study was to demonstrate that canakinumab given upon acute gout flares relieves the signs and symptoms and prevents recurrence of gout flares in patients with frequent flares of gout for whom non-steroidal anti-inflammatory drugs (NSAIDs) and/ or colchicine are contraindicated, not tolerated, or ineffective. The efficacy of canakinumab was compared to the corticosteroid triamcinolone acetonide.

The purpose of the first 12-week extension study was to collect additional safety, tolerability and efficacy data in patients who have completed the core study CACZ885H2356.

The purpose of the second 48 week open-label extension study was to collect additional long-term safety and tolerability data in patients who have completed the first extension study CACZ885H2356E1.

Trial website

https://clinicaltrials.gov/study/NCT01029652

Trial related presentations / publications

Chakraborty A, Van LM, Skerjanec A, Floch D, Klein UR, Krammer G, Sunkara G, Howard D. Pharmacokinetic and pharmacodynamic properties of canakinumab in patients with gouty arthritis. J Clin Pharmacol. 2013 Dec;53(12):1240-51. doi: 10.1002/jcph.162. Epub 2013 Sep 30.

Public notes

Contacts

Principal investigator

Name

Novartis Pharmaceuticals

Address

Novartis Pharmaceuticals

Country

Phone

Contact person for public queries

Name

Address

Country

Phone

Contact person for scientific queries

No information has been provided regarding IPD availability

What supporting documents are/will be available?

No Supporting Document Provided

Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results are available at https://clinicaltrials.gov/study/NCT01029652

Trial Review

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01029652